| Prev Close | 1.89 |
| Open | 1.94 |
| Day Low/High | 1.78 / 1.95 |
| 52 Wk Low/High | 0.23 / 2.31 |
| Volume | 4.19M |
T2 Biosystems, Inc. (TTOO)
1.84
0.05
2.60
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 147.96B |
| Market Cap | 267.80M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Fingers Crossed for a Couple $2 Lottery Tickets in My Portfolio
T2 Biosystems and Tyme Technologies have both perked up of late after languishing for extended periods of time.
Let's See Whether Small-Cap Resurgence Continues
The Russell 2000 had a strong week last week, but whether smaller names can outperform their large-cap brethren going forward remains to be seen.
2 Downtrodden Small Biotechs That Are Showing Signs of Life
T2 Biosystems and Replimune Group have spurted higher in the last couple weeks, with the former doubling in value on encouraging news.
A Good Day for Biotechs
The market has strengthened a bit since our last update. T2 Biosystems is now up over 50% on positive developments that we chronicled in my last post. Lexicon Pharmaceuticals is up some 30% today off oversold levels. It should receive some $260 mil...
Why 3 Biotechs Are Rallying Today
It's a decent start to the trading day as all the major indices are slightly in the green. We are seeing a lot of small biotech stocks I have profiled in these pages rallying on news. Let's start with T2 Biosystems . It is up 25% today as it was awa...
Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
2 Small Biotechs With Sagging Shares but Promising Prospects
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'
Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
Small Biotechs Finally Join in Market Rebound
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
2 Stocks I'm Buying This Week as Investors Flee Small-Cap Biotechs
This is why I always have some 'dry powder' to deploy during these temporary hiccups.
Consider These Diagnostic Testing Firms
Diagnostic firms can have an advantage of recurring revenue streams.
3 Small Biotechs Turn on the Revenue Jets
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
How to Play Biotech 'Sell the News' Pattern
Patient investors can profit from small-cap biotech stocks that often slide once positive news comes out.
3 Busted IPOs with 10-Bagger Potential
Verastem Inc., T2 Biosystems Inc. and Resonant Inc. have great long-term growth prospects.
How to Manage Risk in Biotech Stocks
T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.
Two Antibiotic Plays
They may not get all the attention, but antibiotic drugs are increasingly important.
How to Manage Risk in Biotech
T2 Biosystems used the run-up on a positive event - an FDA approval - to raise additional capital.
3 of My Favorite Medical Diagnostic Plays
These equities have been in rally mode since April.
Three Stocks on the Move
Markets off to a decent start to the trading day with all the major indices up a half hour into trading. Some of the names I have profiled in recent months are on the move early today. Let's take a look at a few of these: T2 Biosystems after posting...
3 Promising Biotech Stocks to Buy on Dips
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
Three Biotech Opportunities
Celgene, ANI and T2 are seeing attractive entry points.
Biotech Shows Strength
The major indices have improved a tad since our last update. Biotech has shown some strength over the past two hours or so. There are two names to keep an eye on: T2 Biosystems has been strong so far in 2018, moving from around $4 to over $5 a shar...
Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?
After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.
2 Biotech 'Busted IPOs' to Watch in 2018
Are these names the next 'Ignytas'?
The Best Part of the Biotech Rally This Year Is Probably Over
The Nasdaq Biotech Index is up 25% so far this year
Biotech Mailbag: Buy Dip in T2 Biosystems?
Plus, what's going on with Lexicon Pharmaceuticals?
2 Small Biotechs Under $5 May Be Bargains
T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.
Rally Likely To Be Short-Lived
The charts indicate more weakness is on the way.
